Effects of Royal Jelly Administration on Lipid Profile, Satiety, Inflammation, and Antioxidant Capacity in Asymptomatic Overweight Adults

Table 5

Inflammatory and anti-inflammatory markers in asymptomatic subjects before and after intervention.

	CRP (μg/L)		Adiponectin (μg/mL)		Bilirubin (μmol/L)		UA (μmol/L)
	Placebo	Royal jelly	Placebo	Royal jelly	Placebo	Royal jelly	Placebo	Royal jelly
Initial	1.25±0.54	1.59±0.66	12.0±6.3	12.8±5.8	12.0±5.3	7.8±4.5	346±76	294±84
Week 4	1.37±0.83	1.36±0.52	11.8±6.4	13.6±6.4	9.2±4.9	9.6±5.0	293±69	293±60
Week 8	1.32±0.76	1.28±0.42	8.9±6.5	17.2±6.7	9.4±6.0	10.5±5.2	302±53	310±74
F/U	1.48±0.73	1.25±0.31	8.5±5.1	16.7±6.8	8.0±4.3	8.2±4.7	320±70	316±57

Abbreviation: CRP, C-reactive protein; F/U, follow up; UA, uric acid.
Values are expressed as means ± SD.
p-value denotes significant (p<0.05) difference between the change from baseline on royal jelly vs. placebo.
p-value denotes significant (p<0.05) difference as compared with the initial within group using a paired t-test.
p-value denotes significant (p<0.05) difference between the two groups (royal jelly vs. placebo) at a given time point.